REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
(WorldNews Belgium)

INDIANAPOLIS, Oct. 6, 2020 /PRNewswire/ -- Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 7.2 times greater odds, respectively, of achieving superior pain freedom at 2 hours post treatment compared to those taking placebo in at least 2 out of 3 attacks (co-primary endpoint), new findings from the recently completed Phase 3 study CENTURION reveal. This co-primary endpoint result translated to therapeutic gains, or differences between REYVOW and placebo groups, of approximately 10-20%. Moreover, in at least 2 out of 3 attacks, Eli Lilly and Company`s (NYSE: LLY) REYVOW demonstrated superiority over placebo in pain relief at 2 hours....